Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer | Zendy

Alexander Drilon | Zendy; Geoffrey R. Oxnard | Zendy; Daniel Shao-Weng Tan | Zendy; Herbert H. Loong | Zendy; Melissa L. Johnson | Zendy; Justin F. Gainor | Zendy; Caroline E. McCoach | Zendy; Oliver Gautschi | Zendy; Benjamin Besse | Zendy; Byoung Chul Cho | Zendy; Nir Peled | Zendy; Jared Weiss | Zendy; Yu-Jung Kim | Zendy; Yuichiro Ohe | Zendy; Makoto Nishio | Zendy; Keunchil Park | Zendy; Jyoti D. Patel | Zendy; Takashi Seto | Zendy; Tomohiro Sakamoto | Zendy; Ezra Rosen | Zendy; Manisha H. Shah | Zendy; Fabrice Barlési | Zendy; Philippe A. Cassier | Zendy; Lyudmila Bazhenova | Zendy; Filippo de Braud | Zendy; Elena Garralda | Zendy; Vamsidhar Velcheti | Zendy; Miyako Satouchi | Zendy; Kadoaki Ohashi | Zendy; Nathan A. Pennell | Zendy; Karen L. Reckamp | Zendy; Grace K. Dy | Zendy; Jürgen Wolf | Zendy; Benjamin Solomon | Zendy; Gerald S. Falchook | Zendy; Kevin Ebata | Zendy; Michele Nguyen | Zendy; Binoj C. Nair | Zendy; Edward Y. Zhu | Zendy; Luxi Yang | Zendy; Xin Huang | Zendy; Elizabeth Olek | Zendy; S. Michael Rothenberg | Zendy; Kōichi Goto | Zendy; Vivek Subbiah | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

Author(s) -

Alexander Drilon,

Geoffrey R. Oxnard,

Daniel Shao-Weng Tan,

Herbert H. Loong,

Melissa L. Johnson,

Justin F. Gainor,

Caroline E. McCoach,

Oliver Gautschi,

Benjamin Besse,

Byoung Chul Cho,

Nir Peled,

Jared Weiss,

Yu-Jung Kim,

Yuichiro Ohe,

Makoto Nishio,

Keunchil Park,

Jyoti D. Patel,

Takashi Seto,

Tomohiro Sakamoto,

Ezra Rosen,

Manisha H. Shah,

Fabrice Barlési,

Philippe A. Cassier,

Lyudmila Bazhenova,

Filippo de Braud,

Elena Garralda,

Vamsidhar Velcheti,

Miyako Satouchi,

Kadoaki Ohashi,

Nathan A. Pennell,

Karen L. Reckamp,

Grace K. Dy,

Jürgen Wolf,

Benjamin Solomon,

Gerald S. Falchook,

Kevin Ebata,

Michele Nguyen,

Binoj C. Nair,

Edward Y. Zhu,

Luxi Yang,

Xin Huang,

Elizabeth Olek,

S. Michael Rothenberg,

Kōichi Goto,

Vivek Subbiah

Publication year - 2020

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2005653

Subject(s) - medicine , lung cancer , confidence interval , chemotherapy , adverse effect , oncology , gastroenterology , response evaluation criteria in solid tumors , clinical endpoint , hazard ratio , clinical trial , phases of clinical research

RET fusions are oncogenic drivers in 1 to 2% of non-small-cell lung cancers (NSCLCs). In patients with RET fusion-positive NSCLC, the efficacy and safety of selective RET inhibition are unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research